Sun Pharmaceutical and Moebius Medical received FDA Fast Track designation for MM-II, a treatment for osteoarthritis knee pain, facilitating its development and review process. The drug showed significant efficacy in a Phase 2b study, providing pain relief for up to 26 weeks after a single injection.